ALLMedicine™ Shigellosis Center

Jun 22nd, 2022 - Shigella flexneri has become a significant public health concern accounting for the majority of shigellosis cases worldwide. Even though a multitude of efforts is being made into the development of a vaccine to prevent infections, the absence of a...

Jun 22nd, 2022 - The purpose of this study is to determine if ShigActive is safe and effective in healthy adults in a continuous Phase 1/2a trial. Phase 1 will asses the safety of ShigActive in healthy adults, while Phase 2a will evaluate the safety and efficacy o...

Jun 8th, 2022 - ShigETEC vaccine is intended to stimulate an immune response in which protective antibodies are generated that prevent infection if a vaccinee is subsequently exposed to Shigella and ETEC. Main objective of the study: In Stage 1 is to determine Ma...

Jun 7th, 2022 - Shigella is a well-known etiological agent responsible for intestinal infection among children, the elderly, and immunocompromised people ranging from mild to severe cases. Shigellosis remains endemic in Malaysia and yet there is no commercial vac...

May 10th, 2022 - Shigella species, which cause acute diarrheal disease, are transmitted via fecal-oral and sexual contact. To better understand the overlapping populations affected by Shigella infections and sexually transmitted infections (STIs) in the United Sta...

Jun 22nd, 2022 - The purpose of this study is to determine if ShigActive is safe and effective in healthy adults in a continuous Phase 1/2a trial. Phase 1 will asses the safety of ShigActive in healthy adults, while Phase 2a will evaluate the safety and efficacy o...

Jun 8th, 2022 - ShigETEC vaccine is intended to stimulate an immune response in which protective antibodies are generated that prevent infection if a vaccinee is subsequently exposed to Shigella and ETEC. Main objective of the study: In Stage 1 is to determine Ma...

Apr 25th, 2022 - The aim of the current clinical study is to evaluate, for the first time in humans (FTIH), the safety and immunogenicity of the altSonflex1-2-3 candidate vaccine against S. sonnei and S. flexneri serotypes 1b, 2a, and 3a. The vaccine will be first...

Apr 22nd, 2022 - This is a double-blind placebo-controlled trial to evaluate the safety, reactogenicity, immunogenicity and efficacy of a 10^6 cfu dose of an oral live-attenuated S. sonnei vaccine candidate, WRSs2, in up to 120 healthy males and non-pregnant femal...

Apr 13th, 2022 - Specific Objectives: Primary objective To determine whether tebipenem-pivoxil is non-inferior to the currently WHO-recommended second line Shigella therapy (ceftriaxone) Secondary objectives: Describe the number of adverse events, between children...

Sep 22nd, 2021 - Evacuees of Afghanistan who have arrived in the United States must be vaccinated against measles and undergo quarantine for 21 days, according to a health advisory issued September 20 by the Centers for Disease Control and Prevention (CDC). At the...

Aug 7th, 2018 - General supportive care of patients with shigellosis includes: Infection with Shigella is normally self-limited. The average duration of gastrointestinal symptoms of untreated shigellosis is 7 days Antibiotic treatment is indicated in some patient...

Apr 21st, 2017 - The Centers for Disease Control and Prevention has identified an increase in Shigella isolates with reduced susceptibility to ciprofloxacin, and has released an official health advisory outlining new recommendations for clinical diagnosis, managem.

Feb 24th, 2017 - More than 10% of patients developed irritable bowel syndrome (IBS) within a year after infectious enteritis, which gave them a more than fourfold greater risk than that of controls, according to a systematic review and meta-analysis of 45 studies.

Feb 24th, 2017 - More than 10% of patients developed irritable bowel syndrome (IBS) within a year after infectious enteritis, which gave them a more than fourfold greater risk than that of controls, according to a systematic review and meta-analysis of 45 studies.